AngioDynamics, Inc. (ANGO) vs 4D Molecular Therapeutics, Inc. (FDMT)
A side-by-side comparison of AngioDynamics, Inc. and 4D Molecular Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
ANGO
AngioDynamics, Inc.
$14.83HealthcareDelayed quote: Oct 6, 2026, 11:25 AM EDT
FDMT
4D Molecular Therapeutics, Inc.
$12.93HealthcareDelayed quote: Oct 6, 2026, 11:25 AM EDT
Total return — ANGO vs FDMT
growth of $100 · dividends reinvested · last 6yANGO +5.6% (+0.9%/yr)FDMT -68.1% (-17.3%/yr)ANGO compounded faster over this window
ANGO FDMT
ANGO vs FDMT: by the numbers
- •FDMT is the larger company ($676M vs $613M market cap).
- •Both run net losses; ANGO's is the smaller (-11.48% vs -194.74% net margin).
- •FDMT grew revenue faster over the past five years (31.93% vs 1.93% CAGR).
Metrics side by side
Valuation
| Metric | ANGO | FDMT |
|---|---|---|
| P/S ratio | 1.91 | 7.35 |
| P/B ratio | 3.59 | 1.66 |
| FCF yield | 0.08% | N/A |
Profitability
| Metric | ANGO | FDMT |
|---|---|---|
| Gross margin | 54.62% | 91.05% |
| Operating margin | -12.47% | -187.24% |
| Net margin | -11.48% | -194.74% |
| ROE | -21.51% | -43.95% |
| ROIC | -20.75% | -44.30% |
Growth (annualized)
| Metric | ANGO | FDMT |
|---|---|---|
| Revenue CAGR (5Y) | 1.93% | 31.93% |
| FCF CAGR (5Y) | -51.49% | N/A |
| Total return CAGR (5Y) | -10.80% | -13.08% |
Frequently asked
- Which has grown faster, ANGO or FDMT?
- Over the past five years, FDMT grew revenue faster — ANGO at a 1.93% CAGR versus FDMT at 31.93%.
- How have ANGO and FDMT total returns compared?
- Over the past 5 years, ANGO delivered -10.80% and FDMT delivered -13.08% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
AngioDynamics ROE4D Molecular Therapeutics ROEAngioDynamics operating margin4D Molecular Therapeutics operating marginAngioDynamics revenue growth4D Molecular Therapeutics revenue growthAngioDynamics free cash flow4D Molecular Therapeutics free cash flow
AngioDynamics & 4D Molecular Therapeutics appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.